Saad Usmani

Chief Attending

Memorial Sloan Kettering Cancer Center

United States

Research Interests

Explore related searches

Professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Saad Usmani serves as Chief Attending at Memorial Sloan Kettering Cancer Center in the United States. He specializes in multiple myeloma research, focusing on therapeutic combinations and predictive modeling of treatment effects. His recent publications explore the efficacy of various treatment regimens and their impact on patient outcomes, including the role of novel agents in both newly diagnosed and transplant-ineligible myeloma cases.

Articles (10)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Collaborators (5)

Bachisio Ziccheddu

Sylvester Comprehensive Cancer Center, University of Miami

UNITED STATES

View details

ROBERTO MINA

Assistant professor

ITALY

View details

Robert Orlowski

Florence Maude Thomas Cancer Research Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES

View details

Benjamin Derman

Assistant Professor

University of Chicago

UNITED STATES

View details

Michael E. O'Dwyer

National University of Ireland Galway

IRELAND

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Saad Usmani

Research Interests

Explore related searches

Contact this professor

About

Articles (10)

Current and future role of carfilzomib‐based quadruplet combinations as therapy for newly diagnosed multiple myeloma

Modeling MRD Changes in Myeloma to Understand Treatment Effects, Predict Outcomes, and Investigate Curative Potential

Author Correction: Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS trial

Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS trial

Daratumumab/lenalidomide/dexamethasone in transplant-ineligible newly diagnosed myeloma: MAIA long-term outcomes

Daratumumab plus lenalidomide/dexamethasone in untreated multiple myeloma: analysis of key subgroups of the MAIA study

High WEE1 expression is independently linked to poor survival in multiple myeloma

Impact of Rare Structural Variant Events in Newly Diagnosed Multiple Myeloma

Addition of elotuzumab to backbone treatment regimens for multiple myeloma: an updated meta-analysis of randomized clinical trials

Pre-diagnosis dietary patterns and risk of multiple myeloma in the NIH-AARP diet and health study

Collaborators (5)

Bachisio Ziccheddu

ROBERTO MINA

Robert Orlowski

Benjamin Derman

Michael E. O'Dwyer

Make your next move.